SafetyTector™ S Cat. No. #400 ONLY for OEM

SafetyTector™ SafetyTector™ S is a SARS-CoV-2 inactivating extraction and dilution buffer for saliva specimens and nasopharyngeal swabs. Swabs can be extracted directly with SafetyTector™ S. Samples must be diluted in SafetyTector™ S at least 1:4. At this dilution, SafetyTector™ S is able to inactivate SARS-CoV-2 within 1 minute. Therefore the samples are no longer infectious.
£0.00

Choose your options

SafetyTector™

SafetyTector™ S is a SARS-CoV-2 inactivating extraction and dilution buffer for saliva specimens and nasopharyngeal swabs. Swabs can be extracted directly with SafetyTector™ S.


SafetyTector™ S eliminates the high risk of infection during and after testing coming from the specimen or other test materials. Virus inactivation was confirmed and tested with infectious viruses in a Biosafety Level 3 laboratory.

SafetyTector™ S completely eliminates infectivity of SARS-CoV-2

Samples diluted in SafetyTector™ S can directly be used in lateral flow assays and also in other immunoassays such as ELISA, protein arrays oder bead-based assays.

In tests with commercially available SARS-CoV-2 antigen rapid tests, SafetyTector™ S shows comparable or better performance than supplied extraction and dilution buffers. In some cases, further improvement in the detection limit was observed.

The suitability of SafetyTector™ S for the respective assay has to be tested by the manufacturer or distributor.

Safe Design of in vitro diagnostic medical devices (IVD products) is an obligatory pre-requisite for placing them on the international markets in the EU. This is defined in EU legislation (Directive 98/79/EG, Annex I, chapter B, clause 2.1 and Regulation (EU) 2017/746, Annex I, Chapter I, clause 4). Besides that, the ISO 14971 „application of risk management to medical devices“ (ISO 14971:2012, Annex A, chapter A.2.6 risk control) - decisive for the correct implementation of the ISO 13485 - mandates a risk control procedure and thus gives another regulatory binding basis for ensuring that IVDs are safe and secure for the user in all international markets. Safe Design includes that the risk of infection for the user is eliminated or reduced to the lowest possible level – this is especially important for IVDs for highly infectious viruses such as SARS-CoV-2. The current pandemic situation with the highly infectious variants of SARS-CoV-2 forces immediate action even for IVD products already on the market.

Virus-inactivating extraction buffers are an easy-to-use and effective tool to produce IVDs in conformity with these mandatory regulations.
During the past there were no virus-inactivating extraction buffers, proven to be able to inactivate SARS-CoV-2 by experiments under real conditions with infective viruses, available on the market.

SafetyTector™ S thus sets a current state of the art in terms of safe design for user safety during antibody- and antigen-tests – especially in rapid lateral flow testing. Testing virus inactivation with substitute test materials such as virus-like particles (VLPs) cannot safely allow the same conclusions in terms of user safety.
Together with SafetyTector™ S, manufacturers of IVD directly get the necessary evidence for virus inactivation in form of a “Letter of Acknowledgement” from the testing Biosafety Level 3 laboratory.


Download Product Resources

 SARS-CoV-2 antigen tests: safety for less than 5 cents per test 

Product Descriptions & Guides

Product Inserts and Data Sheets

Brand CANDOR Bioscience
Code 400 902

Product Flyers and Application Guides

 BIOAXXESS CANDOR Blocker Selection Guide NEW
BIOAXXESS CANDOR Product Application Guide
 CANDOR Products Brochure
 Assay Defender® Flyer NEW
 Assay Defender® Use NEW
 Assay Defender® LowCross-Buffer® Comparison Matrix NEW
 SafetyTector™ S NEW
 


Product Inserts and Data Sheets

Assay Optimizers

 Assay Defender® Cat. No. #180  NEW
 LowCross-Buffer® Cat. No. #100, #101, #102
 LowCross-Buffer® Animal-free/Protein-free Cat. No. #300, #301, #302
 Low-Cross-HRP® Cat. No. #200
 LowCross® HRP-Stab Cat. No. #270
 LowCross® HRP-Stab Animal-free/Protein-free Cat. No. #370
 Sample Buffer Cat. No. #105, #106
 Sample Buffer Animal-free/Protein-free Cat. No. #305


Covid-19 Inactivation and Dilution Buffer

 SafetyTector™ S Cat. No. #400  NEW
 

Blockers

 The Blocking Solution Cat. No. #110
 BSA-Block Cat. No. #115
 PlateBlock™ Cat. No. #112  NEW  
 SmartBlock™ Cat. No. #113


Stabilizers

 Antibody Stabilizer TRIS Cat. No. #130
 Antibody Stabilizer TRIS Animal-free/Protein-free Cat. No. #330
 Antibody Stabilizer PBS Cat. No. #131
 Antibody Stabilizer PBS Animal-free/Protein-free Cat. No. #331
 AP-Protector® Cat. No. #235
 Liquid Plate Sealer® Cat. No. #160
 Liquid Plate Sealer® Animal-free Cat. No. #163
 HRP-Protector™ Cat. No. #222
 HRP-Protector™ Animal-free/Protein-free Cat. No. #322


Standard Buffers (ready-made)

 Coating Buffer pH 7.4 Cat. No. #120
 Coating Buffer pH 9.6 Cat. No. #121
 Stripping Buffer Cat. No. #150
 Washing Buffer PBS Cat. No. #140
 Washing Buffer PBS IHC Cat. No. #141
 Washing Buffer TRIS Cat. No. #145
 Washing Buffer TRIS IHC Cat. No. #146


All-in-One Western Blotting Solution

 ReadyTector® Cat. No. #720 and 730


Tool boxes

 Blocking Sampler Package with BSA Block Cat. No. #600
 CANDOR Starter Package Cat. No. #600
 CANDOR Starter Package IHC Cat. No. #600


Publications

 CoViD-19-antibody-test-challenge
 Interference and HAMA problems
 IVD Technology Article
 Long-term stabilization of assay components
 Optimisation of assays: Interference in immunoassays recognize and avoid 
 SARS-CoV-2 antigen tests: safety for less than 5 cents per test 
 Specificity, positive predictive value and validation statistics in the context of CoViD-19
 The Appropriate Blocker — A Short Overview
 The right strategy saves much costs